NCT04430166

PD-1 Monoclonal Antibody in Pre-treated Lymphoepithelioma-like Carcinoma

A Exploratory Clinical Study on PD-1 Monoclonal Antibody in Pre-treated Lymphoepithelioma-like Carcinoma

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 12 (estimated)
• Sponsor: Guangzhou University of Traditional Chinese Medicine · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Lymphoepithelioma-like carcinoma (LELC) may benefit from immunocheckpoint inhibitor therapy. Although target antibody drugs for PD-1 and PD-L1 have achieved good results in immunotherapy of many malignant tumors, there is still a lack of corresponding clinical research reports on whether LELC treatment can benefit. Therefore, this study intends to adopt the basket research model , to explore the application of anti-procedural death receptor 1 (PD-1) monoclonal antibody in patients with advanced LELC after the failure of first-line standard treatment . Further explore the relationship between tumor and body immunity, tumor microenvironment and curative effect, and find stable biomarkers, so as to screen out the superior population of tumor immunotherapy.

Conditions

• Lymphoepithelioma-Like Carcinoma

Interventions

Type	Name	Description
DRUG	PD-1 monoclonal antibody	200mg / intravenous drip, once every three weeks

Timeline

• Start date: 2020-06-01
• Primary completion: 2022-09-01
• Completion: 2022-10-01
• First posted: 2020-06-12
• Last updated: 2020-06-12

Locations

1 site across 1 country: China